Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Chase, Thomas N ^a   Oh, Justin D ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; PROTEIN KINASE (CALCIUM,CALMODULIN) II;

CONFERENCE PAPER; DOPAMINERGIC SYSTEM; HUMAN; LONG TERM POTENTIATION; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CORPUS STRIATUM; DOPAMINE AGENTS; HUMANS; LEVODOPA; MOTOR NEURONS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 0034105156     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (92)

1. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997;20:523-530
2. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998;51(Suppl 2):S30-S35
3. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(Suppl 2):S25-S29
4. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376
5. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479
6. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371
7. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988;24:372-378
8. Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526
9. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(Suppl 6):S15-S18
10. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctutions in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31
11. Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372
12. Chase TN, Juncos J, Serrati C, et al. Fluctuations in response to chronic levodopa therapy. Adv Neurol 1986;45:477-480
13. Chase TN, Mouradian MM, Fabbrini G, Juncos JL. Pathogenetic studies of motor fluctuations in Parkinson's disease. J Neural Transm Suppl 1988;27:3-10
14. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478
15. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989;168:291-298
16. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74
17. Marin C, Papa SM, Engber TM, et al. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996;736:202-205
18. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44:163-196
19. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 1990;13:259-265
20. Graybiel AM, Aosaki T, Flaherty AW, Kimura M. The basal ganglia and adaptive motor control. Science 1994;265:1826-1831
21. Cervo L, Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res 1996;731:31-38
22. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to basal ganglionic disorders. Trends Neurosci 1996;19:19-24
23. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
24. Engber TM, Susel Z Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxy-dopamine lesioned rats. Brain Res 1991;552:113-118
25. Le Moine C, Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 1995;355:418-426
26. Engber TM, Boldry RC, Kuo S, Chase TN. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992;581:261-268
27. Engber TM, Boldry RC, Chase TN. The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists. Eur J Pharmacol 1991;200:171-173
28. Marin C, Engber TM, Chaudhuri P, et al. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology (Berl) 1996;123:215-221
29. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7
30. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956
31. Onofrj M, Paci C, Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;65: 605-606
32. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 1984;4:2866-2876
33. Schultz W. Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris) 1994;150:634-639
34. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
35. Zigmond MJ, Abercrombie ED, Stricker EM. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa. J Neural Transm Suppl 1990;29:217-232
36. Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989; 39(Suppl 2):7-10
37. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(Suppl 1):1-9
38. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science 1970;170:76-77
39. Ng KY, Chase TN, Colburn RW, Kopin IJ. Dopamine: stimulation-induced release from central neurons. Science 1971;172:487-489
40. Ng LK, Chase TN, Colburn RW, Kopin IJ. L-Dopa in Parkinsonism. A possible mechanism of action. Neurology 1972; 22:688-696
41. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980;8:558-563
42. Wachtel SR, Abercrombie ED. L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994;63:108-117
43. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxy-dopamine-treated rats. Brain Res 1990;525:36-44
44. McEachern JC, Shaw CA. An alternative to the LTP orthodoxy: a plasticity-pathology continuum model. Brain Res Brain Res Rev 1996;22:51-92
45. Wang JH, Ko GY, Kelly PT. Cellular and molecular bases of memory: synaptic and neuronal plasticity. J Clin Neurophysiol 1997;14:264-293
46. Castro-Alamancos MA, Donoghue JP, Connors BW. Different forms of synaptic plasticity in somatosensory and motor areas of the neocortex. J Neurosci 1995;15:5324-5333
47. Calabresi P, Saiardi A, Pisani A, et al. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 1997;17:4536-4544
48. Asanuma H, Pavlides C. Neurobiological basis of motor learning in mammals. Neuroreport 1997;8:i-vi
49. Nicoll RA, Malenka RC. Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature 1995;377: 115-118
50. Cain DP. LTP, NMDA, genes and learning. Curr Opin Neurobiol 1997;7:235-242
51. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588
52. Boldry RC, Papa SM, Kask AM, Chase TN. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Res 1995;692:259-264
53. Papa SM, Boldry RC, Engber TM, et al. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18
54. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501
55. Cepeda C, Levine MS. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 1998;20: 1-18
56. Lloyd KG, Willigens MT, Goldstein M. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey. Psychopharmacology Suppl 1985;2:200-210
57. Clarke CE, Sambrook MA, Mitchell IJ, Crossman ARH. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280
58. Gomez-Mancilla B, Bédard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427
59. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578
60. Blanchet PJ, Papa SM, Metman LV, et al. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 1997;21:447-453
61. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802
62. Blanchet PJ, Metman LV, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581
63. Verhagen Metman L, Blanchet PJ, van den Munckhof P, et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998;13:414-417
64. Verhagen Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206
65. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326
66. Carroll CB, Holloway V, Brotchie JM, Mitchell IJ. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berl) 1995;119:55-65
67. Greenamyre JT, O'Brien CF. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48: 977-981
68. Mitchell IJ, Carroll CB. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 1997; 21:469-475
69. Blanchet PJ, Konitsiotis S, Whitmore N, et al. Different effects of subunit specific NMDA antagonists in parkinsonian monkeys. J Pharmacol Exp Ther 1999; in press
70. Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992;213:439-443
71. Greulich W, Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm Suppl 1995;46:415-421
72. Danysz W, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 1997;21:455-468
73. Wollmuth LP, Kuner T, Seeburg PH, Sakmann B. Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels. J Physiol (Lond) 1996;491:779-797
74. Chen Q, Reiner A. Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res 1996;743: 346-352
75. Raymond LA, Tingley WG, Blackstone CD, et al. Glutamate-receptor modulation by protein-phosphorylation. J Physiol Paris 1994;88:181-192
76. Gurd JW. Protein tyrosine phosphorylation: implications for synaptic function. Neurochem Int 1997;31:635-649
77. Suen PC, Wu K, Xu JL, et al. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res Mol Brain Res 1998;59: 215-228
78. Wang YT, Salter MW. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature 1994;369:233-235
79. Yu XM, Askalan R, Keil GJ 2nd, Salter MW. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 1997;275:674-678
80. 2+ calmodulin-dependent protein-kinase-II. Mol Cell 1995;5:475-480
81. Hisatsune C, Umemori H, Inoue T, et al. Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin. J Biol Chem 1997;272:20805-20810
82. Tingley WG, Ehlers MD, Kameyama K, et al. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 1997;272:5157-5166
83. Menegoz M, Lau LF, Herve D, Huganir RL, Girault JA. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 1995;7:125-128
84. Oh JD, Russell D, Vaughan CL, Chase TN. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and levodopa administration. Brain Res 1998;813:150-159
85. Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 1999;821:433-442
86. Ulas J, Cotman C. Dopaminergic denervatiom of striatum results in elevated expression of NR2A subunit. Neuroreport 1996;7: 1789-1793
87. Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 1997;228:5-8
88. Suzuki T, Okumura-Noji K. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the post-synaptic density fraction isolated from the rat brain. Biochem Biophys Res Commun 1995;216:582-588
89. Kohr G, Seeburg PH. Subtype-specific regulation of recombinant NMDA receptor-channels by protein tyrosine kinases of the src family. J Physiol (Lond) 1996;492:445-452
90. Yu XM, Askalan R, Keil GJ, Salter MW. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 1997;275:674-678
91. Tan SE, Chen SS. The activation of calcium/calmodulin-dependent protein-kinase II after glutamate or potassium stimulation in hippocampal slices. Brain Res Bull 1997;43:269-273
92. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23